Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Follistatin 315

Activin-Binding Protein, FSH-Suppressing Protein, FST-315, FS-315

Quick Stats
Studies 14
Trials 93
Completed PHASE4 INTERVENTIONAL NCT06174961

The Effect of Exercise on Pharmacodynamics and Pharmacokinetics of a Single Dose of Unfractionated Heparin

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

The aim of this project is to assess the influence of exercise on pharmacokinetics (PK) and pharmacodynamics (PD) of a single dose of subcutaneously (sc) administered unfractionated heparin (UFH). It is hypothesized that exercise will increase the systemic exposure (PK) and therefore the clinical effects (PD) of the sc administered UFH. To assess this, healthy male volunteers will be included in a controlled, randomized, crossover study, where they, on four separate days, will have UFH injected sc in the thigh, followed by different exercise interventions (one per experimental day). Blood sampling, with the aim of assessing PK and PD will be performed during the following hours.

Interventions

Name: Unfractionated heparin
Type: DRUG
Description: 15,000 units of unfractionated heparin administered in the thigh
Name: Double-legged cycle ergometer exercise
Type: BEHAVIORAL
Description: One hour of double-leg cycle ergometer exercise
Name: Single-legged cycle ergometer exercise, with unfractionated heparin injection in the exercising leg
Type: BEHAVIORAL
Description: One hour of single-leg cycle ergometer exercise, after unfractionated heparin injection in the ipsilateral leg
Name: Single-legged cycle ergometer exercise, with unfractionated heparin injection in the non-exercising leg
Type: BEHAVIORAL
Description: One hour of single-leg cycle ergometer exercise, after unfractionated heparin injection in the ipsilateral leg
Name: No exercise
Type: BEHAVIORAL
Description: No exercise

Primary Outcomes

Measure: Difference between interventions in change in incremental activated partial thromboplastin time (aPTT)
TimeFrame: Peak aPTT for 1-8 hours after unfractionated heparin (UFH) injection
Description:

Trial Information

NCT ID

NCT06174961

Status

Completed

Study Type

INTERVENTIONAL

Phases

PHASE4

Sponsor

Kristian Karstoft

Last Updated

December 15, 2025

Related Peptides